Progress of research on the gut microbiome and its metabolite short-chain fatty acids in postmenopausal osteoporosis: a literature review.
10.1007/s11684-025-1129-3
- Author:
Yao CHEN
1
;
Ying XIE
1
;
Xijie YU
2
Author Information
1. Laboratory of Endocrinology and Metabolism/Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, 610041, China.
2. Laboratory of Endocrinology and Metabolism/Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, 610041, China. xijieyu@hotmail.com.
- Publication Type:Review
- Keywords:
Th17 cells;
Treg cells;
gut microbiota;
postmenopausal osteoporosis;
short-chain fatty acids
- MeSH:
Humans;
Gastrointestinal Microbiome/immunology*;
Fatty Acids, Volatile/metabolism*;
Osteoporosis, Postmenopausal/immunology*;
Female;
T-Lymphocytes, Regulatory/metabolism*;
Th17 Cells/metabolism*;
Dysbiosis/immunology*;
Bone and Bones/metabolism*
- From:
Frontiers of Medicine
2025;19(3):474-492
- CountryChina
- Language:English
-
Abstract:
Postmenopausal osteoporosis (PMOP) is a systemic metabolic bone disease caused by the decrease in estrogen levels after menopause. It leads to bone loss, microstructural damage, and an increased risk of fractures. Studies have found that the gut microbiota and its metabolites can regulate bone metabolism through the gut-bone axis and the gut-brain axis. As research progresses, PMOP has been found to be associated with gut microbiota dysbiosis and Th17/Treg imbalance. The gut microbiota is closely related to the development and differentiation of Treg and Th17 cells. Among them, the metabolites of the gut microbiota such as short-chain fatty acids (SCFAs) can regulate the differentiation of effector T cells by acting on molecular receptors on immune cells, thereby regulating the bone immune process. The multifaceted relationship among the gut microbiota, SCFAs, Th17/Treg cell-mediated bone immunity, and bone metabolism is eliciting attention from researchers. Through a review of existing literature, we have comprehensively summarized the effects of the gut microbiota and SCFAs on PMOP, especially from the perspective of Th17/Treg balance. Regulating this balance may provide new opportunities for PMOP treatment.
